Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AT 753

Next Previous
Drug Profile

AT 753

Alternative Names: AT-753

Latest Information Update: 02 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Audentes Therapeutics
  • Developer Astellas Gene Therapies
  • Class Antisense oligonucleotides; Gene therapies
  • Mechanism of Action Dystrophin expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 01 Aug 2022 Discontinued - Preclinical for Duchenne muscular dystrophy in USA (Parenteral) prior to August 2022
  • 01 Apr 2021 Audentes Therapeutics is now called Astellas Gene Therapies
  • 10 Dec 2020 Audentes Therapeutics plans to initiate clinical trials for Duchenne muscular dystrophy, in the 2021 financial year

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top